Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of 16.76 billion. The enterprise value is 19.91 billion.
| Market Cap | 16.76B |
| Enterprise Value | 19.91B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Dec 3, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 3.80% |
| Owned by Institutions (%) | 18.59% |
| Float | 200.34M |
Valuation Ratios
The trailing PE ratio is 36.83 and the forward PE ratio is 19.66.
| PE Ratio | 36.83 |
| Forward PE | 19.66 |
| PS Ratio | 3.81 |
| PB Ratio | 7.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.66 |
| P/OCF Ratio | 13.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.25, with an EV/FCF ratio of 19.79.
| EV / Earnings | 42.62 |
| EV / Sales | 4.59 |
| EV / EBITDA | 15.25 |
| EV / EBIT | 17.84 |
| EV / FCF | 19.79 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 1.51.
| Current Ratio | 0.74 |
| Quick Ratio | 0.41 |
| Debt / Equity | 1.51 |
| Debt / EBITDA | 2.47 |
| Debt / FCF | 3.25 |
| Interest Coverage | 11.32 |
Financial Efficiency
Return on equity (ROE) is 20.21% and return on invested capital (ROIC) is 16.60%.
| Return on Equity (ROE) | 20.21% |
| Return on Assets (ROA) | 9.84% |
| Return on Invested Capital (ROIC) | 16.60% |
| Return on Capital Employed (ROCE) | 22.70% |
| Weighted Average Cost of Capital (WACC) | 6.56% |
| Revenue Per Employee | 254,647 |
| Profits Per Employee | 27,048 |
| Employee Count | 17,270 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, Coloplast has paid 117.77 million in taxes.
| Income Tax | 117.77M |
| Effective Tax Rate | 20.14% |
Stock Price Statistics
The stock price has decreased by -20.04% in the last 52 weeks. The beta is 0.57, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -20.04% |
| 50-Day Moving Average | 6.87 |
| 200-Day Moving Average | 6.76 |
| Relative Strength Index (RSI) | 59.17 |
| Average Volume (20 Days) | 309,372 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of 4.40 billion and earned 467.11 million in profits. Earnings per share was 0.20.
| Revenue | 4.40B |
| Gross Profit | 2.92B |
| Operating Income | 1.13B |
| Pretax Income | 584.88M |
| Net Income | 467.11M |
| EBITDA | 1.28B |
| EBIT | 1.13B |
| Earnings Per Share (EPS) | 0.20 |
Balance Sheet
The company has 77.65 million in cash and 3.27 billion in debt, with a net cash position of -3.19 billion.
| Cash & Cash Equivalents | 77.65M |
| Total Debt | 3.27B |
| Net Cash | -3.19B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.17B |
| Book Value Per Share | 0.96 |
| Working Capital | -533.97M |
Cash Flow
In the last 12 months, operating cash flow was 1.22 billion and capital expenditures -210.61 million, giving a free cash flow of 1.01 billion.
| Operating Cash Flow | 1.22B |
| Capital Expenditures | -210.61M |
| Depreciation & Amortization | 145.47M |
| Net Borrowing | -235.09M |
| Free Cash Flow | 1.01B |
| FCF Per Share | n/a |
Margins
Gross margin is 66.50%, with operating and profit margins of 25.73% and 10.62%.
| Gross Margin | 66.50% |
| Operating Margin | 25.73% |
| Pretax Margin | 13.30% |
| Profit Margin | 10.62% |
| EBITDA Margin | 29.08% |
| EBIT Margin | 25.73% |
| FCF Margin | 23.15% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 4.60%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 4.60% |
| Dividend Growth (YoY) | -2.99% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 36.63% |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 4.60% |
| Earnings Yield | 2.72% |
| FCF Yield | 6.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Coloplast is 8.51, which is 12.84% higher than the current price. The consensus rating is "Hold".
| Price Target | 8.51 |
| Price Target Difference | 12.84% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 6.78% |
| EPS Growth Forecast (3Y) | 5.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Coloplast has an Altman Z-Score of 3.56 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 6 |